Tomita Masaki, Shimizu Tetsuya, Ayabe Takanori, Onitsuka Toshio
Department of Surgery II, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Gen Thorac Cardiovasc Surg. 2010 Nov;58(11):573-6. doi: 10.1007/s11748-010-0647-2. Epub 2010 Nov 11.
The prognostic significance of the combined use of preoperative platelet count and serum carcinoembryonic antigen (CEA) level in non-small-cell lung cancer patients was investigated.
Consecutive 289 non-small-cell lung cancer patients were reviewed retrospectively. Thrombocytosis was defined as a platelet count of at least 40 × 10(4)/mm(3).
The frequency of preoperative thrombocytosis was 4.5% (13/289). The 5-year survival of patients with thrombocytosis was 30.77%, which was significantly poorer than that of patients with normal counts (68.65%, P = 0.0010). The 5-year survivals of patients with a normal CEA level and those with an elevated serum CEA level were 74.18% and 55.78%, respectively (P = 0.0019). Patients with both a normal platelet count and a normal serum CEA level had a favorable prognosis, whereas those with both thrombocytosis and elevated serum CEA level had a poor prognosis. The prognostic impact of the combined use of the platelet count and the serum CEA level was more significant than that of the platelet count or the serum CEA level alone. Both univariate and multivariate analyses indicated an independent prognostic impact of the combined use of platelet count and serum CEA levels.
The combined use of preoperative platelet count and serum CEA levels might be useful for predicting the prognosis of non-small-cell lung cancer patients.
研究术前血小板计数和血清癌胚抗原（CEA）水平联合应用对非小细胞肺癌患者的预后意义。
回顾性分析289例连续的非小细胞肺癌患者。血小板增多症定义为血小板计数至少为40×10⁴/mm³。
术前血小板增多症的发生率为4.5%（13/289）。血小板增多症患者的5年生存率为30.77%，显著低于血小板计数正常患者（68.65%，P = 0.0010）。血清CEA水平正常和升高的患者5年生存率分别为74.18%和55.78%（P = 0.0019）。血小板计数和血清CEA水平均正常的患者预后良好，而血小板增多症且血清CEA水平升高的患者预后较差。血小板计数和血清CEA水平联合应用的预后影响比单独使用血小板计数或血清CEA水平更显著。单因素和多因素分析均表明血小板计数和血清CEA水平联合应用具有独立的预后影响。
术前血小板计数和血清CEA水平联合应用可能有助于预测非小细胞肺癌患者的预后。
